Latest News

Australia retreats as CSL delays spin-off of vaccine division

The Australian share market fell on Tuesday. Biotech giant CSL was the main culprit, as it weighed down the healthcare sub-index. CSL hit a low of nearly seven years after delaying the spin-off of its vaccine division.

By 2353 GMT, the S&P/ASX 200 index had fallen 0.3% to 9,032.40. The benchmark closed Monday 0.4% higher.

The shares of the biotech giant CSL fell as much as 16.6%, to A$176.23. This is their lowest level since December 24, 2018. After the firm announced that it does not expect to complete the spinoff CSL Seqirus by fiscal 2026 due to increased volatility on the U.S. flu vaccine market.

The company was also the biggest loser in the benchmark index, causing the healthcare sub-index to drop as much as 7.9% and reach its lowest level since Nov. 2, 2023.

The technology stocks dropped around 3.6%. WiseTech Global shares fell up to 16.3%, reaching A$71.17. This was their lowest level since 7 April, and they were among the worst performers on the benchmark.

The Australian corporate regulator is investigating the firm, and so are federal police. They executed a search order for documents relating to alleged share trading by the founder Richard White and other employees.

Gold stocks fell 5.6% on the back of falling bullion prices, which were boosted by signs that tensions between the U.S. and China are easing. This reduced gold's appeal as a safe haven.

The gold miners Evolution Mining (formerly Northern Star Resources) and Evolution Mining fell by 4.3% and 3.8% respectively.

The "Big Four" lenders gained between 1.2% to 2.4%, while the banks saw a gain of 1.6%.

Investors in Australia are now waiting for the third-quarter CPI figures, which will be released on Wednesday, before determining how central banks' interest rates will move.

New Zealand's benchmark S&P/NZX 50 was mostly flat at 13,392.44 point.

(source: Reuters)